Early study checks how food affects new drug AZD5004
NCT ID NCT07455825
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested different oral versions of the drug AZD5004 in 65 healthy adults. The goal was to see how the body absorbs and processes each version, and whether taking it with food changes those effects. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AZD5004
- What this could lead to
- If successful, this study could help determine the best way to take AZD5004 in future trials, possibly leading to a new treatment option.
- What could go wrong
- This is an early Phase 1 study in healthy people, not patients. It only looks at how the drug moves through the body, not whether it works for any disease. Results may not apply to patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
65 people
The number who actually took part.
- Started
-
Mar 2026
- Finished
-
Jun 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Main Inclusion Criteria: * Participants suitable veins for cannulation or repeated venipuncture. * All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit. * Female participants: 1. of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception, to avoid pregnancy. 2. of non-childbearing potential must be confirmed at the Screening Visit. * Male participants: 1. Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods. 2. Additional contraception must be used for the sexual partners of male study participants throughout the clinical study. * Have a Body Mass Index (BMI) of ≥ 23 kg/m2 but not exceeding 35 kg/m2 inclusive (at the time of Screening) and weigh at least 60 kg. Main Exclusion Criteria: * History of any clinically important disease or disorder which, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. * Any clinically significant illness, medical/surgical procedure, or trauma * Participants who have a special dietary requirement and who are unable/unwilling to follow a uniform diet. * Participants positive for anti- hepatitis B core antibody (anti-HBc) or anti-hepatitis C Virus Antibody (anti-HCV). * Participants who are on or are planning to undertake a weight loss program during the study period. * Abnormal vital signs, after 10 minutes supine rest, at Screening and/or admission to the Clinical Unit. * Positive screen for drugs of abuse, or alcohol or cotinine (nicotine). * Any laboratory values with the deviations specified in protocol and clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy participants are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Glendale, California, 91206, United States
-
Research Site
Baltimore, Maryland, 21225, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does it matter where you inject? scientists test Weight-Loss drug in arm, thigh, and belly
- New drug RO7830698 put to the test for COPD
- Three pill versions of one drug go head to head in the bloodstream
- Pfizer tests RSV vaccine aimed at older adults
- Radioactive tracer maps where a new drug goes in the body
- Radioactive tag lets scientists follow an experimental drug through the human body